<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40890873</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2057-3804</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Cardio-oncology (London, England)</Title><ISOAbbreviation>Cardiooncology</ISOAbbreviation></Journal><ArticleTitle>SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial.</ArticleTitle><Pagination><StartPage>79</StartPage><MedlinePgn>79</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">79</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40959-025-00368-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SGLT2i exerts several cardiometabolic benefits in heart failure with reduced and preserved ejection fraction through the systemic reduction of insulin, visceral fat, chemokines and growth factors involved in cardiovascular diseases. Anthracyclines are considered the principal culprit drugs behind chemotherapy-induced cardiotoxicity. The pathognomonic manifestation of anthracycline-induced cardiotoxicity is a hypokinetic cardiomyopathy progressively leading to heart failure. Anthracycline-induced cardiotoxicity is still a significant problem that compromises the quality of life and overall survival of breast cancer (BC) patients. Sequential therapy regimen of anthracyclines and HER-2 blocking agents is associated to higher risk of cardiotoxicity compared to monotherapy regimen. Recent studies in preclinical models of anthracycline-induced cardiotoxicity concluded that SGLT2i are able to prevent ejection fraction reduction and myocardial inflammation and fibrosis. A very recent retrospective study indicates that SGLT2i were associated with lower rate of cardiac events among patients with cancer and T2DM who were treated with anthracyclines. These data support the conducting of a randomized clinical trial testing Dapagliflozin in patients with breast cancer treated with anthracyclines+/- trastuzumab.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the cardioprotective effects of the SGLT2 inhibitor Dapagliflozin in chemotherapy-naive patients with stage I-III breast cancer undergoing anthracycline-based treatment with or without trastuzumab, by assessing its ability to reduce the incidence of cardiotoxicity and improve systemic cardiometabolic markers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Chemotherapy-naive patients (18-70 years) scheduled for antracycline +/- trastuzumab treatment in the [neo-]adjuvant setting for stage I-III breast cancer, will be randomized using a web-based system stratified by the use of trastuzumab to follow a chemotherapy regimen plus Dapagliflozin [10&#xa0;mg/die] [active group] or chemotherapy regimen plus standard of care [control group]. During follow up period, if a patient develops asymptomatic or symptomatic systolic disfunction will be treated according to good clinical practice. From randomization, to the third, sixth, twelfth and eighteenth months, echocardiographic and cardiological visits will be performed associated to blood analysis for quantification of cardiotoxicity biomarkers (NT-pro-BNP, hsTNI), CKD-EPI eGFR and systemic inflammation (hsCRP, chemokines, cytokines and growth factors).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study is ongoing. Results will be published when the study is completed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The PROTECT trial is the first randomized clinical study designed to evaluate whether Dapagliflozin can reduce anthracycline- and/or trastuzumab-associated cardiotoxicity in patients with early-stage breast cancer. Beyond its established cardiometabolic effects, this trial will also provide insight into the systemic anti-inflammatory and metabolic benefits of SGLT2 inhibition in the oncology setting. Findings from this study may pave the way for novel cardio-oncology strategies aimed at improving both cardiac outcomes and quality of life in cancer patients.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT06341842 [EudraCT Number 2022-003377-28]. Registered on 19 March 2024.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quagliariello</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Oncology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy. g.rizzo@smatteo.pv.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedeschi</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology, "Guglielmo da Saliceto" Hospital, Piacenza, 29121, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schirinzi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turco</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galiazzo</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acquaro</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Amicis</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory Medicine Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klersy</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bio-Statistics and Cinical Trial Center Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghio</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrone</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Oncology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paccone</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uccello</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiology Unit, Alessandro Manzoni Hospital, Lecco, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canale</LastName><ForeName>M L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Cardiology, Versilia Hospital, Azienda USL Toscana Nord-Ovest, Lido di Camaiore, 55041, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliva</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UOSD Cardiologia di Interesse Oncologico, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, 70124, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerra</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cardiology and Arrhythmology Clinic, Marche University Hospital, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Luca</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurea</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiology Division, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scelsi</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cardiology Division, Fondazione Policlinico San Matteo, IRCCS, Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06341842</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>8076023</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiooncology</MedlineTA><NlmUniqueID>101689938</NlmUniqueID><ISSNLinking>2057-3804</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Beast cancer</Keyword><Keyword MajorTopicYN="N">Cardio-oncology</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Trastuzumab</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The Ethics Committee of Fondazione IRCCS Policlinico San Matteo has approved the study and its consent to participate [number 0008491/23]. The study will be conducted in accordance with the Declaration of Helsinki. All researchers are trained and certified in Good Clinical Practices. A written informed consent will be taken from all participants. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>0</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40890873</ArticleId><ArticleId IdType="pmc">PMC12400668</ArticleId><ArticleId IdType="doi">10.1186/s40959-025-00368-9</ArticleId><ArticleId IdType="pii">10.1186/s40959-025-00368-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anchit B, et al. Anthracycline-Induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol. 2020;1257:181&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">32483740</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale D et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25948538</ArticleId></ArticleIdList></Reference><Reference><Citation>Role of cardiovascular imaging. In cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association [HFA], the European Association of Cardiovascular Imaging [EACVI] and the Cardio-Oncology Council of the European Society of Cardiology [ESC]. Eur J Heart Fail. 2020;22:1504&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">32621569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurvitz SA, et al. Neoadjuvant trastuzumab, Pertuzumab, and chemotherapy versus trastuzumab emtansine plus Pertuzumab in patients with HER2-positive breast cancer [KRISTINE]: a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;191:115&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29175149</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Minckwitz G, et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl. J Med. 2017;3772:122&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538020</ArticleId><ArticleId IdType="pubmed">28581356</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer [CLEOPATRA study]: overall survival results from a randomised, double-blind, placebo-controlled, III 3 study. Lancet Oncol. 2013;14(6):461&#x2013;&#x2009;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076842</ArticleId><ArticleId IdType="pubmed">23602601</ArticleId></ArticleIdList></Reference><Reference><Citation>Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">11248153</ArticleId></ArticleIdList></Reference><Reference><Citation>Moja L, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718210</ArticleId><ArticleId IdType="pubmed">22513938</ArticleId></ArticleIdList></Reference><Reference><Citation>Suter TM, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol. 2007;25:3859.&#x2013;&#x2009;3865.</Citation><ArticleIdList><ArticleId IdType="pubmed">17646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander R, Lyon et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association [EHA], the European Society for Therapeutic Radiology and Oncology [ESTRO] and the International Cardio-Oncology Society [IC-OS]: Developed by the task force on cardio-oncology of the European Society of Cardiology [ESC]. Eur Heart J. 2022; ehac244.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1):18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485127</ArticleId><ArticleId IdType="pubmed">31023386</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier B, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial [preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies]. J Am Coll Cardiol. 2013;6123:2355&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">23583763</ArticleId></ArticleIdList></Reference><Reference><Citation>Geeta G, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy [PRADA]: a 2 &#xd7; 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;3721:1671&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887703</ArticleId><ArticleId IdType="pubmed">26903532</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, Liu et al. Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer. Zhonghua Zhong Liu Za Zhi. 2013;35(12):936&#x2013;&#x2009;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">24506965</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthiah V, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. J Am Coll Cardiol CardioOnc. 2019 Sep;1:54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571368</ArticleId><ArticleId IdType="pubmed">33083790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373. 2015;2117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal B et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377. 2017;644&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">28605608</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380. 2019;2295&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">30990260</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380. 2019;347&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">32865377</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurray JJV, et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">31535829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif ME, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">31524498</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O&#x2019;Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder&#xe4;ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. DELIVER trial committees and investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;38712:1089&#x2013;98. 10.1056/NEJMoa2206286.</Citation></Reference><Reference><Citation>Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG. Sodium-Glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;108:559&#x2013;67. 10.1016/j.jchf.2022.03.006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9638993</ArticleId><ArticleId IdType="pubmed">35902159</ArticleId></ArticleIdList></Reference><Reference><Citation>Theresa AMD, ESC Scientific Document Group., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology [ESC] With the special contribution of the Heart Failure Association [HFA] of the ESC. Eur J Heart Fail. Sept 2021; 42(36):3599&#x2013;3726.</Citation></Reference><Reference><Citation>Cherney DZI, et al. Effects of the SGLT2 inhibitor Dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease [DIAMOND]: a randomised, double&#x2010;blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8:582&#x2013;93. 10.1016/S2213-8587[20]30162-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">32559474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif F, Nagueh et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J&#x2013; Cardiovasc Imaging. 2016;17:1321&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">27422899</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur J Heart Fail. 2017;19(1):9&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27565769</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkova M, Russell R 3. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214&#x2013;20. 10.2174/157340311799960645. PMID: 22758622; PMCID: PMC3322439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322439</ArticleId><ArticleId IdType="pubmed">22758622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda J, Oikawa M, Tokuda E, Tachibana K, Sasaki E, Ohtake T, Takeishi Y, Saji S. Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study. Support Care Cancer. 2024;33(1):8. 10.1007/s00520-024-09067-0. PMID: 39648236; PMCID: PMC11625689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11625689</ArticleId><ArticleId IdType="pubmed">39648236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme Inhibition. Circulation. 2006;114(23):2474&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101852</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, et al. Protective effects of the angiotensin II receptor blocker Telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):e4871&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20826257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Cho I, You SC, Cha MJ, Chang JS, Kim WD, Go KY, Kim DY, Seo J, Shim CY, Hong GR, Kang SM, Ha JW, Rha SY, Kim HS. Cancer Therapy-Related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin. Cancers (Basel). 2022;14(9):2320. 10.3390/cancers14092320. PMID: 35565449; PMCID: PMC9100163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9100163</ArticleId><ArticleId IdType="pubmed">35565449</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilis P, Vlachakis PK, Oikonomou E, Drakopoulou M, Karakasis P, Apostolos A, Pamporis K, Tsioufis K, Tousoulis D. Cancer Therapy-Related cardiac dysfunction: A review of current trends in epidemiology, diagnosis, and treatment. Biomedicines. 2024;12(12):2914. 10.3390/biomedicines12122914. PMID: 39767820; PMCID: PMC11673750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11673750</ArticleId><ArticleId IdType="pubmed">39767820</ArticleId></ArticleIdList></Reference><Reference><Citation>Haj-Yehia E, Michel L, Mincu RI, Rassaf T, Totzeck M. Prevention of cancer-therapy related cardiac dysfunction. Curr Heart Fail Rep. 2025;22(1):9. 10.1007/s11897-025-00697-x. PMID: 39969700; PMCID: PMC11839799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11839799</ArticleId><ArticleId IdType="pubmed">39969700</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco A, Canale ML, Quagliariello V, Oliva S, Tedeschi A, Inno A, De Biasio M, Bisceglia I, Tarantini L, Maurea N, Navazio A, Corda M, Iacovoni A, Colivicchi F, Grimaldi M, Oliva F. SGLT2 inhibitors in Cancer patients: A comprehensive review of clinical, biochemical, and therapeutic implications in Cardio-Oncology. Int J Mol Sci. 2025;26(10):4780. 10.3390/ijms26104780. PMID: 40429921; PMCID: PMC12112039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12112039</ArticleId><ArticleId IdType="pubmed">40429921</ArticleId></ArticleIdList></Reference><Reference><Citation>Quagliariello V, Di Mauro A, Ferrara G, Bruzzese F, Palma G, Luciano A, Canale ML, Bisceglia I, Iovine M, Cadeddu Dessalvi C, Maurea C, Barbato M, Inno A, Berretta M, Paccone A, Mauriello A, Fonderico C, Maratea AC, Maurea N. Cardio-Renal and systemic effects of SGLT2i Dapagliflozin on Short-Term anthracycline and HER-2-Blocking agent Therapy-Induced cardiotoxicity. Antioxid (Basel). 2025;14(5):612. 10.3390/antiox14050612. PMID: 40427493; PMCID: PMC12108597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12108597</ArticleId><ArticleId IdType="pubmed">40427493</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtes RA, van Raalte DH, Correa-Rotter R, Toto RD, Heerspink HJL, Cain V, Sj&#xf6;str&#xf6;m CD, Sartipy P, Stef&#xe1;nsson BV. The effects of Dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. Diabetes Obes Metab. 2020;22(4):549&#x2013;56. 10.1111/dom.13923. Epub 2019 Dec 14. PMID: 31742881; PMCID: PMC7078964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078964</ArticleId><ArticleId IdType="pubmed">31742881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrominski JW, Thierer J, Claggett BL, Miao ZM, Desai AS, Jhund PS, Kosiborod MN, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD, Vaduganathan M. Cardio-Renal-Metabolic overlap, outcomes, and Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. JACC Heart Fail. 2023;11(11):1491&#x2013;503. 10.1016/j.jchf.2023.05.015. Epub 2023 May 24. PMID: 37226448.</Citation><ArticleIdList><ArticleId IdType="pubmed">37226448</ArticleId></ArticleIdList></Reference><Reference><Citation>Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, Zafar A, Gong J, Zlotoff DA, Gilman HK, Hartmann SE, Sama S, Nikolaidou S, Suero-Abreu GA, Jacobsen E, Abramson JS, Hochberg E, Barnes J, Armand P, Thavendiranathan P, Nohria A, Neilan TG. Sodium-Glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;10(8):559&#x2013;67. Epub 2022 Jun 8. PMID: 35902159; PMCID: PMC9638993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9638993</ArticleId><ArticleId IdType="pubmed">35902159</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>